of comparable efficacy, methotrexate is preferred over leflunomide because of the evidence supporting its value as an anchor DMARD in combination regimens. Additional advantages of methotrexate include its greater dosing flexibility and lower cost. Methotrexate monotherapy is strongly recommended over bDMARD or tsDMARD monotherapy for DMARD-naive patients with moderate-to-high disease activity There is low-certainty evidence suggesting superiority of tocilizumab monotherapy Methotrexate